Photo of Daniel W. Haupt, M.D.

Daniel W. Haupt M.D.

I attended medical school with the intention to continue my research in cardiology and add clinical practice to my career. However, my exposure to people with mental illness convinced me that I wanted to dedicate myself to improving the care and understanding of mental illness. I became involved in series of clinical studies addressing the medical problems associated with mental illness and its treatment, and received specialized research training at Washington University in St. Louis, where I completed a NIMH funded career development award. I also remained clinically active, providing care and training residents on the inpatient psychiatry service, the psychiatry consultation-liaison service, and a similar consultation service for patients with cancer. I am thrilled to be working at OHSU, where I will have the opportunity to continue to learn about mental illness and help train the next generation of psychiatrists to build on our progress.


  • M.D., University of Vermont College of Medicine, Burlington Vermont 0 1997
  • Residency:

    • Washington University in St. Louis School of Medicine, 2001
  • Certifications:

    • Psychiatry, 2002

Memberships and associations

  • American Psychiatric Association


  • "Metabolic risks and effects of atypical antipsychotic treatment." Journal of Clinical Psychiatry October 2007
  • "Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients" Neuropsychopharmacology December 2007
  • "Early changes in defibrillation threshold following implantation of a nonthoracotomy system in dogs" PACE - Pacing and Clinical Electrophysiology  1994
  • "Hyperglycemia and antipsychotic medications" Journal of Clinical Psychiatry  2001
  • "Recognizing and responding to atypical antipsychotic side effects" Journal of the American Medical Directors Association July 2004
  • "Differential metabolic effects of antipsychotic treatments" European Neuropsychopharmacology September 2006
  • "Risperidone-associated diabetic ketoacidosis [4] (multiple letters)" Psychosomatics  2001
  • "Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia" JAMA Psychiatry  2002
  • "Use of adenosine to identify patients at risk for recurrence of accessory pathway conduction after initially successful radiofrequency catheter ablation" PACE - Pacing and Clinical Electrophysiology  1995
  • "Impact of medical comorbidity on medication management of schizophrenia." CNS Spectrums December 2007
  • "Reply" Neuropsychopharmacology September 2005
  • "Antipsychotic-induced weight gain and metabolic abnormalities" Journal of Clinical Psychiatry  2004
  • "Abnormalities in glucose regulation associated with mental illness and treatment" Journal of Psychosomatic Research October 1 2002
  • "The metabolic effects of antipsychotic medications" Canadian Journal of Psychiatry  2006
  • "Diabetes, psychotic disorders and antipsychotic therapy" Medical Journal of Australia November 15 2004
  • "Perceptions of weight gain and bipolar pharmacotherapy" Current Medical Research and Opinion December 2006
  • "Plasma leptin and adiposity during antipsychotic treatment or schizophrenia" Neuropsychopharmacology January 2005
  • "Prevalence and predictors of Lipid and Glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents" American Journal of Psychiatry March 2009

Additional information

Edit profile